{
    "nctId": "NCT06306274",
    "briefTitle": "Topical Tacrolimus for Breast Cancer-related Lymphedema",
    "officialTitle": "Topical Tacrolimus for the Amelioration of Breast Cancer-related Lymphedema: a Randomized, Double-blind, Placebo-controlled Phase II/III Trial",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Lymphedema",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Lymphedema volume",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age over 18 years\n* BCRL ISL stage I or II\n* Pitting edema\n* Postmenopausal or use of Contraceptive drugs\n* Healthy opposite arm\n* L-Dex score over 10\n\nExclusion Criteria:\n\n* Pregnant, breast-feeding, or aiming to conceive within the next year\n* Bilateral breast cancer\n* Contralateral lymphadenectomy\n* Allergy to tacrolimus, macrolides, or iodine\n* Pacemaker\n* Known kidney or liver disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}